StockData
Collegium Pharmaceutical, Inc logo

Collegium Pharmaceutical, Inc (COLL) stock

COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$25.43+0.11 (+0.43%)

Close on Nov 16, 2026Market cap $827.89MP/E 20.5Yield –

Collegium Pharmaceutical operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Collegium Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was $157.44M, up 21.3% year over year. For fiscal 2025 it was $179.64M, up 5.7% from the year before. The highest annual figure on record is $179.64M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$179.64M+5.7%
FY2024Dec 31, 2024$169.90M+1.8%
FY2023Dec 31, 2023$166.96M+401.1%
FY2022Dec 31, 2022$33.32M+89.0%
FY2021Dec 31, 2021$17.63M-68.7%
FY2020Dec 31, 2020$56.23M–
FY2019Dec 31, 2019-$23.75M–
FY2018Dec 31, 2018-$20.69M–
FY2017Dec 31, 2017-$75.45M–
FY2016Dec 31, 2016-$94.08M–
FY2015Dec 31, 2015-$26.91M–
FY2014Dec 31, 2014-$17.67M–
FY2013Dec 31, 2013-$16.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.70M-89.5%
Q1 FY2026Mar 31, 2026$30.90M+42.5%
Q4 FY2025Dec 31, 2025$60.76M+59.4%
Q3 FY2025Sep 30, 2025$62.09M+78.2%
Q2 FY2025Jun 30, 2025$35.11M-26.0%
Q1 FY2025Mar 31, 2025$21.69M-56.2%
Q4 FY2024Dec 31, 2024$38.11M-38.2%
Q3 FY2024Sep 30, 2024$34.84M-22.6%
Q2 FY2024Jun 30, 2024$47.47M+33.2%
Q1 FY2024Mar 31, 2024$49.47M+100.9%
Q4 FY2023Dec 31, 2023$61.69M+424.7%
Q3 FY2023Sep 30, 2023$45.01M+119.9%
Q2 FY2023Jun 30, 2023$35.63M+220.7%
Q1 FY2023Mar 31, 2023$24.63M–
Q4 FY2022Dec 31, 2022$11.76M–
Q3 FY2022Sep 30, 2022$20.47M+44.7%
Q2 FY2022Jun 30, 2022$11.11M-32.3%
Q1 FY2022Mar 31, 2022-$10.02M-147.3%
Q4 FY2021Dec 31, 2021-$34.12M-327.5%
Q3 FY2021Sep 30, 2021$14.15M-27.9%
Q2 FY2021Jun 30, 2021$16.41M-0.8%
Q1 FY2021Mar 31, 2021$21.19M+318.7%
Q4 FY2020Dec 31, 2020$15.00M–
Q3 FY2020Sep 30, 2020$19.63M–
Q2 FY2020Jun 30, 2020$16.55M–
Q1 FY2020Mar 31, 2020$5.06M–
Q4 FY2019Dec 31, 2019-$2.37M-121.6%
Q3 FY2019Sep 30, 2019-$6.38M–
Q2 FY2019Jun 30, 2019-$5.01M–
Q1 FY2019Mar 31, 2019-$9.99M–
Q4 FY2018Dec 31, 2018$11.00M–
Q3 FY2018Sep 30, 2018-$11.19M–
Q2 FY2018Jun 30, 2018-$7.29M–
Q1 FY2018Mar 31, 2018-$13.21M–
Q4 FY2017Dec 31, 2017-$17.58M–
Q3 FY2017Sep 30, 2017-$13.43M–
Q2 FY2017Jun 30, 2017-$21.26M–
Q1 FY2017Mar 31, 2017-$23.18M–
Q4 FY2016Dec 31, 2016-$27.58M–
Q3 FY2016Sep 30, 2016-$26.44M–

More Collegium Pharmaceutical figures

See a number that looks wrong?